Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Pratt

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|February 16, 2008
IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14)Sylvia Feyler, Sheila J M O'Connor, Andy C Rawstron, et al.
Blood Cancer Journal|March 16, 2023
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemicJonathan Carmichael, Frances Seymour, Graham McIlroy, et al.
Blood Cancer Journal|November 5, 2020
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient managementIlaria J Chicca, Jennifer L J Heaney, Gulnaz Iqbal, et al.
Blood|July 5, 2008
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markersChris Pepper, Thet Thet Lin, Guy Pratt, et al.
The British Journal of Radiology|August 14, 2018
National survey of imaging practice for suspected or confirmed plasma cell malignanciesOlwen Amy Westerland, Guy Pratt, Majid Kazmi, et al.
British Journal of Haematology|January 3, 2024
Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology servicesMark Drayson, Tom Jennis, Ira Laketic-Ljubojevic, et al.
British Journal of Haematology|April 25, 2009
Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rateJulio Delgado, Guy Pratt, Neil Phillips, et al.
Value in Health Regional Issues|February 25, 2023
An Economic Model to Establish the Costs Associated With Routes to Presentation for Patients With Multiple Myeloma in the United KingdomAlex Porteous, Scott Gibson, Lucy A Eddowes, et al.
British Journal of Haematology|August 17, 2020
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trialCatherine Atkin, Gulnaz Iqbal, Tim Planche, et al.
British Journal of Haematology|March 26, 2017
Telomere length is a critical determinant for survival in multiple myelomaSam Hyatt, Rhiannon E Jones, Nicole H Heppel, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|February 16, 2008
IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14)Sylvia Feyler, Sheila J M O'Connor, Andy C Rawstron, et al.
Blood Cancer Journal|March 16, 2023
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemicJonathan Carmichael, Frances Seymour, Graham McIlroy, et al.
Blood Cancer Journal|November 5, 2020
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient managementIlaria J Chicca, Jennifer L J Heaney, Gulnaz Iqbal, et al.
Blood|July 5, 2008
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markersChris Pepper, Thet Thet Lin, Guy Pratt, et al.
The British Journal of Radiology|August 14, 2018
National survey of imaging practice for suspected or confirmed plasma cell malignanciesOlwen Amy Westerland, Guy Pratt, Majid Kazmi, et al.
British Journal of Haematology|January 3, 2024
Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology servicesMark Drayson, Tom Jennis, Ira Laketic-Ljubojevic, et al.
British Journal of Haematology|April 25, 2009
Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rateJulio Delgado, Guy Pratt, Neil Phillips, et al.
Value in Health Regional Issues|February 25, 2023
An Economic Model to Establish the Costs Associated With Routes to Presentation for Patients With Multiple Myeloma in the United KingdomAlex Porteous, Scott Gibson, Lucy A Eddowes, et al.
British Journal of Haematology|August 17, 2020
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trialCatherine Atkin, Gulnaz Iqbal, Tim Planche, et al.
British Journal of Haematology|March 26, 2017
Telomere length is a critical determinant for survival in multiple myelomaSam Hyatt, Rhiannon E Jones, Nicole H Heppel, et al.
Pageof 14